<DOC>
	<DOCNO>NCT02696616</DOCNO>
	<brief_summary>Investigation safety tolerability BI 655088 follow intravenous infusion single rising dos exploration pharmacokinetics pharmacodynamics BI 655088 single dosing</brief_summary>
	<brief_title>Single Rising Dose Study BI 655088 Administered Intravenously Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male subject Age 18 50 year Body mass index ( BMI ) 18.5 29.9 kg/m2 Additional inclusion criterion may apply Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg diastolic blood pressure outside range 50 90 mmHg pulse rate outside range 45 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological disorder psychiatric disorder Additional exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>